| HOME >> BIOLOGY >> TECHNOLOGY |
aniasis.
Further information about VioQuest can be found at http://www.vioquestpharm.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve
risks and uncertainties that could cause VioQuest's actual results and
experiences to differ materially from the anticipated results and
expectations expressed in these forward-looking statements. These
statements are often, but not always, made through the use of words or
phrases such as anticipates, expects, plans, believes, intends, and similar
words or phrases. These statements are based on current expectations,
forecasts and assumptions that are subject to risks and uncertainties,
which could cause actual outcomes and results to differ materially from
these statements. In addition, this press release also includes
forward-looking statements regarding the timing, progress and results of
the clinical development, regulatory processes, potential clinical trial
initiations, potential IND and NDA filings and commercialization efforts of
VioQuest's drug development product candidates. These statements are
subject to various risks and uncertainties and include the possibility that
the results of clinical trials will not support VioQuest's claims, the
possibility that VioQuest's development efforts relating to its product
candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be
successful, the inability to obtain regulatory approval of VioQuest's
product candidates, VioQuest's reliance on third-party researchers to
develop its product candidates, its lack of experience in developing and
commercializing pharmaceutical products, and the possibility that its
licenses to develop and commercialize its product candidates may be
terminated. Additional risks are described in VioQuest's Annual Report on
Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no
obligation and does not intend to upda
'/>"/>
| SOURCE VioQuest Pharmaceuticals Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |